Cardiol Therapeutics Inc. Class A Common Shares (CRDL)

Price$1.11

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-3.95%

Price vs S&P 500 (4W)-12.77%

VGM Score54.22

Market Capitalization$129.45M

All Metrics

Book Value / Share (Quarterly)$0.16

P/TBV (Annual)6.12x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.16

Price vs S&P 500 (YTD)12.49%

EPS (TTM)$-0.28

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-0.28

EPS (Annual)$-0.37

ROI (Annual)-147.38%

Net Profit Margin (5Y Avg)-143204.20%

Cash / Share (Quarterly)$0.18

ROA (Last FY)-115.11%

EBITD / Share (TTM)$-0.27

ROE (5Y Avg)-100.84%

Cash Flow / Share (Annual)$-0.17

P/B Ratio7.44x

P/B Ratio (Quarterly)8.73x

Net Income / Employee (Annual)$-1,464,439

Net Interest Coverage (TTM)-0.89x

ROA (TTM)-165.39%

EPS Incl Extra (Annual)$-0.37

Current Ratio (Annual)4.16x

Quick Ratio (Quarterly)3.93x

3-Month Avg Trading Volume0.11M

52-Week Price Return-16.04%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.22

P/S Ratio (Annual)2251.43x

Asset Turnover (Annual)0.00x

52-Week High$2.33

Operating Margin (5Y Avg)-156141.00%

EPS Excl Extra (Annual)$-0.37

CapEx CAGR (5Y)-9.35%

Tangible BV CAGR (5Y)11.86%

26-Week Price Return3.97%

Quick Ratio (Annual)3.83x

13-Week Price Return15.44%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)4.39x

Enterprise Value$109.64M

Book Value / Share Growth (5Y)-15.08%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-39550.00%

Cash / Share (Annual)$0.15

3-Month Return Std Dev67.09%

Net Income / Employee (TTM)$-1,451,359

ROE (Last FY)-148.32%

Net Interest Coverage (Annual)-9.71x

EPS Basic Excl Extra (Annual)$-0.37

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.28

Receivables Turnover (Annual)0.00x

ROI (TTM)-227.30%

Pretax Margin (5Y Avg)-143204.20%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.22

Price vs S&P 500 (52W)-40.41%

Year-to-Date Return19.85%

5-Day Price Return-7.10%

EPS Normalized (Annual)$-0.37

ROA (5Y Avg)-81.50%

Net Profit Margin (Annual)-39550.00%

Month-to-Date Return-7.10%

Cash Flow / Share (TTM)$-0.31

EBITD / Share (Annual)$-0.40

Operating Margin (Annual)-48325.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-100.13%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.28

P/TBV (Quarterly)6.12x

P/B Ratio (Annual)7.33x

Book Value / Share (Annual)$0.13

Price vs S&P 500 (13W)7.19%

Beta1.89x

Revenue / Share (TTM)$0.00

ROE (TTM)-229.16%

52-Week Low$1.23

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

4.11

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRDLCardiol Therapeutics Inc. Class A Common Shares	—	—	C	$1.11
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Cardiol Therapeutics is a late-stage biopharmaceutical company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, is advancing through Phase III trials for pericarditis treatment and has completed Phase II studies in myocarditis and heart failure. The company is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart conditions.